Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders. It offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment for adult patients with major depressive disorder. The company's NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed MRI-strength magnetic field, which induces electrical currents designed to stimulate specific areas of the brain associated with mood. Neuronetics, Inc. was incorporated in 2003 and is headquartered in Malvern, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:STIM
Previous Symbol
CUSIPN/A
Phone610-640-4202
Debt
Debt-to-Equity Ratio0.33
Current Ratio7.63
Quick Ratio7.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$40.43 million
Price / Sales8.10
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees167
Outstanding Shares17,580,000
Market Cap$318.19 million
OptionableNot Optionable
Neuronetics (NASDAQ:STIM) Frequently Asked Questions
What is Neuronetics' stock symbol?
Neuronetics trades on the NASDAQ under the ticker symbol "STIM."
How were Neuronetics' earnings last quarter?
Neuronetics Inc (NASDAQ:STIM) announced its quarterly earnings results on Tuesday, November, 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.11. The company had revenue of $13.74 million for the quarter, compared to the consensus estimate of $12.68 million. View Neuronetics' Earnings History.
When is Neuronetics' next earnings date?
What guidance has Neuronetics issued on next quarter's earnings?
Neuronetics updated its FY 2018 earnings guidance on Tuesday, November, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $51-52.5 million, compared to the consensus revenue estimate of $50.95 million.
What price target have analysts set for STIM?
5 analysts have issued 1 year price targets for Neuronetics' stock. Their forecasts range from $33.00 to $40.00. On average, they anticipate Neuronetics' share price to reach $36.3333 in the next year. This suggests a possible upside of 93.9% from the stock's current price. View Analyst Price Targets for Neuronetics.
What is the consensus analysts' recommendation for Neuronetics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Neuronetics.
What are Wall Street analysts saying about Neuronetics stock?
Here are some recent quotes from research analysts about Neuronetics stock:
- 1. According to Zacks Investment Research, "Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics, Inc. is based in Malvern, United States. " (11/10/2018)
- 2. BTIG Research analysts commented, "$33 PT Q3 revenue topped our estimate on both system sales and treatment sessions. Based on a number of conversations with investors, we sensed there was some concern heading into Q3 on what mix might look like (capital vs. procedure sales) and the overall sequential ramp but we feel results in the quarter confirm our view that sales expansion continues to bear fruit. On that initiative, mgmt added 4 more territories in Q3, fairly consistent with our expectations. Additionally, progress towards Japan reimbursement remains on-track with a decision on reimbursement expected in December and formal commencement in March. Until Japan commercialization begins, mgmt highlighted active preparation efforts as well as the strong level of interest among treating docs. Overall, Q3 results were strong, in our view." (11/7/2018)
Has Neuronetics been receiving favorable news coverage?
News stories about STIM stock have trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Neuronetics earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Neuronetics' key competitors?
Some companies that are related to Neuronetics include AtriCure (ATRC), Nevro (NVRO), Luminex (LMNX), K2M Group (KTWO), Orthofix Medical (OFIX), Cryolife (CRY), Tactile Systems Technology (TCMD), Cardiovascular Systems (CSII), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT) and Antares Pharma (ATRS).
Who are Neuronetics' key executives?
Neuronetics' management team includes the folowing people:
- Mr. Christopher A. Thatcher, CEO, Pres & Director (Age 53)
- Mr. Peter L. Donato, VP & CFO (Age 48)
- Mr. Gregory Harper, VP of R&D, Operations and Product Devel. (Age 57)
- Mr. Stephen MacKinnon, VP of Sales
- Ms. Cassie Hallberg, VP of Marketing
When did Neuronetics IPO?
(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.
When does the company's lock-up period expire?
Neuronetics' lock-up period expires on Tuesday, December 25th. Neuronetics had issued 5,500,000 shares in its IPO on June 28th. The total size of the offering was $93,500,000 based on an initial share price of $17.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.
Who are Neuronetics' major shareholders?
Neuronetics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (2.70%), Franklin Resources Inc. (2.35%), BlackRock Inc. (2.32%), FMR LLC (2.12%), Wells Fargo & Company MN (1.98%) and Jennison Associates LLC (1.46%). Company insiders that own Neuronetics stock include Daniel Guthrie and Wilfred E Jaeger. View Institutional Ownership Trends for Neuronetics.
Which major investors are selling Neuronetics stock?
Which major investors are buying Neuronetics stock?
STIM stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Point72 Asset Management L.P., Osterweis Capital Management Inc., Capital Research Global Investors, Franklin Resources Inc., Bellevue Group AG, Wells Fargo & Company MN and United Services Automobile Association. Company insiders that have bought Neuronetics stock in the last two years include Daniel Guthrie and Wilfred E Jaeger. View Insider Buying and Selling for Neuronetics.
How do I buy shares of Neuronetics?
Shares of STIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Neuronetics' stock price today?
One share of STIM stock can currently be purchased for approximately $18.74.
How big of a company is Neuronetics?
Neuronetics has a market capitalization of $318.19 million and generates $40.43 million in revenue each year. Neuronetics employs 167 workers across the globe.
What is Neuronetics' official website?
How can I contact Neuronetics?
Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The company can be reached via phone at 610-640-4202 or via email at [email protected]
MarketBeat Community Rating for Neuronetics (NASDAQ STIM)
MarketBeat's community ratings are surveys of what our community members think about Neuronetics and other stocks. Vote "Outperform" if you believe STIM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe STIM will underperform the S&P 500 over the long term. You may vote once every thirty days.
